A glucagon analogue decreases body weight in mice via signalling in the liver
Abstract Glucagon receptor agonists show promise as components of next generation metabolic syndrome pharmacotherapies. However, the biology of glucagon action is complex, controversial, and likely context dependent. As such, a better understanding of chronic glucagon receptor (GCGR) agonism is esse...
Guardado en:
Autores principales: | Charlotte E. Hinds, Bryn M. Owen, David C. D. Hope, Philip Pickford, Ben Jones, Tricia M. Tan, James S. Minnion, Stephen R. Bloom |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/8c5c2844790d4fd68305731ce059ecb1 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Insulin therapy and body weight: benefits of biphasic human insulin analogue NovoMix 30
por: Elena Viktorovna Surkova
Publicado: (2013) -
Effects of metformin on body weight in patients with type 2 diabetes mellitus,receiving insulin analogue treatment
por: Tatiana Ivanovna Romantsova, et al.
Publicado: (2013) -
Body weight gain rather than body weight variability associated with increased risk of nonalcoholic fatty liver disease
por: Eun Ju Cho, et al.
Publicado: (2021) -
Basal hypersecretion of glucagon and insulin from palmitate-exposed human islets depends on FFAR1 but not decreased somatostatin secretion
por: H. Kristinsson, et al.
Publicado: (2017) -
THE ESTABLISHMENT OF SALES MARKUPS OF GUARANTEEING ELECTRICITY SUPPLIERS BY METHOD OF COMPARISON OF ANALOGUES: DECREASE OR INCREASE
por: O. O. Mozgovaya, et al.
Publicado: (2020)